[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA202191870A1 - Антитела к fgf19 - Google Patents

Антитела к fgf19

Info

Publication number
EA202191870A1
EA202191870A1 EA202191870A EA202191870A EA202191870A1 EA 202191870 A1 EA202191870 A1 EA 202191870A1 EA 202191870 A EA202191870 A EA 202191870A EA 202191870 A EA202191870 A EA 202191870A EA 202191870 A1 EA202191870 A1 EA 202191870A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fgf19
antibodies
well
terminus
antigen
Prior art date
Application number
EA202191870A
Other languages
English (en)
Inventor
Цзяньхуа Суй
Хуэйси Лю
Original Assignee
Хуахуэй Хэлс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хуахуэй Хэлс Лтд. filed Critical Хуахуэй Хэлс Лтд.
Publication of EA202191870A1 publication Critical patent/EA202191870A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Предложены антитела к FGF19, селективно нацеленные на N-конец фактора роста фибробластов 19 (FGF19), а также их антигенсвязывающие фрагменты. Также предложены композиции и варианты применения указанных антител, а также способы лечения заболевания или нарушения, вызванных или связанных с аномальной передачей сигнала FGF19-FGFR4, например злокачественного новообразования, путем введения антител к FGF19.
EA202191870A 2019-02-02 2020-02-02 Антитела к fgf19 EA202191870A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019074530 2019-02-02
PCT/CN2020/074154 WO2020156539A1 (en) 2019-02-02 2020-02-02 Anti-fgf19 antibodies

Publications (1)

Publication Number Publication Date
EA202191870A1 true EA202191870A1 (ru) 2021-12-15

Family

ID=71840807

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191870A EA202191870A1 (ru) 2019-02-02 2020-02-02 Антитела к fgf19

Country Status (6)

Country Link
US (1) US20220041706A1 (ru)
EP (1) EP3917956A4 (ru)
JP (1) JP2022523750A (ru)
CN (1) CN113710701A (ru)
EA (1) EA202191870A1 (ru)
WO (1) WO2020156539A1 (ru)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007254005B2 (en) * 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same
CA2693852C (en) * 2007-08-03 2016-11-29 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
BRPI0908312A2 (pt) * 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
WO2012154263A1 (en) * 2011-05-10 2012-11-15 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta-klotho

Also Published As

Publication number Publication date
WO2020156539A1 (en) 2020-08-06
EP3917956A1 (en) 2021-12-08
EP3917956A4 (en) 2022-12-07
US20220041706A1 (en) 2022-02-10
CN113710701A (zh) 2021-11-26
JP2022523750A (ja) 2022-04-26

Similar Documents

Publication Publication Date Title
EA202092410A1 (ru) Конъюгаты камптотецина с пептидом
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
EA200500488A1 (ru) Фармацевтические составы модафинила
AR085281A1 (es) Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
EA202290054A1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
ECSP099769A (es) Anticuerpos anti-cd44 hibridos y humanizados que median la citotoxicidad de celulas de cancer
EA202192137A1 (ru) Конъюгат аматоксинового аналога с разветвленными линкерами
NZ594682A (en) Fully human antibodies specific to cadm1
PH12021550244A1 (en) Anti-btla antibody
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
EA202190335A1 (ru) Композиции антител против fcrn и способы их применения
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
EA202193111A1 (ru) Композиции и способы для лечения рака
PE20180576A1 (es) ANTICUERPOS MONOCLONALES ESPECIFICOS PARA EL ANTIGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, UTILES PARA LA DETECCION Y EL DIAGNOSTICO DE LA INFECCION CAUSADA POR VRSh
CO2022005113A2 (es) Métodos de tratamiento para modificar la hemodinámica
MX2022002418A (es) Composiciones y metodos de tratamiento de enfermedades vasculares.
ZA202110285B (en) Antibodies and methods of use
MX2023005273A (es) Composiciones farmaceuticas de un inhibidor de cinasa.
EA202191870A1 (ru) Антитела к fgf19
RU2011104709A (ru) Фармацевтическая композиция для лечения и предупреждения рака